PD-1 阻断在无应答者中的影响：陷阱与希望。
Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise.
机构信息
Department of Oncology, Mayo Clinic, Rochester, Minnesota.
Department of Immunology, Mayo Clinic, Rochester, Minnesota.
出版信息
Clin Cancer Res. 2022 Aug 2;28(15):3173-3175. doi: 10.1158/1078-0432.CCR-22-0932.
Abstract
Exploratory analysis of a phase III trial in esophageal cancer found that the patients who most contributed to an overall survival benefit from PD-1 blockade were not responders, but non-responders. The analysis has limitations but may have implications for investigating the optimal timing of immunotherapy relative to other treatments. See related article by Okada et al., p. 3277.
摘要
一项关于食管癌的 III 期临床试验的探索性分析发现，从 PD-1 阻断中获益最大的总体生存患者不是应答者，而是无应答者。该分析存在局限性，但可能对研究免疫治疗相对于其他治疗的最佳时机具有启示意义。请参阅 Okada 等人的相关文章，第 3277 页。
相似文献
1
Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise.PD-1 阻断在无应答者中的影响：陷阱与希望。
Clin Cancer Res. 2022 Aug 2;28(15):3173-3175. doi: 10.1158/1078-0432.CCR-22-0932.
2
Immunotherapy in Squamous Cell Cancer of the Esophagus.食管鳞癌的免疫治疗。
Curr Oncol. 2022 Mar 30;29(4):2461-2471. doi: 10.3390/curroncol29040200.
3
Emerging data on nivolumab for esophageal squamous cell carcinoma.纳武利尤单抗治疗食管鳞癌的新数据。
Expert Rev Gastroenterol Hepatol. 2021 Aug;15(8):845-854. doi: 10.1080/17474124.2021.1948836. Epub 2021 Jul 12.
4
Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.纳武利尤单抗治疗日本食管癌患者的长期疗效和应答预测因素分析。
Cancer Sci. 2020 May;111(5):1676-1684. doi: 10.1111/cas.14380. Epub 2020 Apr 29.
5
Identification of serum microRNAs predicting the response of esophageal squamous-cell carcinoma to nivolumab.鉴定血清 microRNAs 预测食管鳞癌对纳武利尤单抗的反应。
Jpn J Clin Oncol. 2020 Feb 17;50(2):114-121. doi: 10.1093/jjco/hyz146.
6
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.纳武利尤单抗对比化疗用于既往化疗后进展或不耐受的晚期食管鳞癌患者（ATTRACTION-3）：一项多中心、随机、开放标签、III 期临床研究。
Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30.
7
Nivolumab for the treatment of esophageal cancer.纳武利尤单抗治疗食管癌。
Expert Opin Biol Ther. 2021 Jun;21(6):697-703. doi: 10.1080/14712598.2021.1904887. Epub 2021 Mar 29.
8
Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3).纳武利尤单抗治疗既往治疗的晚期食管鳞癌患者的 3 年随访和应答生存关系（ATTRACTION-3）。
Clin Cancer Res. 2022 Aug 2;28(15):3277-3286. doi: 10.1158/1078-0432.CCR-21-0985.
9
Anti-PD-1 immunotherapy in advanced esophageal squamous cell carcinoma: A long-awaited breakthrough finally arrives.晚期食管鳞状细胞癌的抗程序性死亡蛋白1免疫疗法：期待已久的突破终于到来。
J Formos Med Assoc. 2020 Feb;119(2):565-568. doi: 10.1016/j.jfma.2019.10.010. Epub 2019 Oct 23.
10
Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.促进抗 PD-1 治疗的疗效：纳武利尤单抗联合放疗治疗晚期非小细胞肺癌 - FORCE 试验研究方案。
BMC Cancer. 2019 Nov 8;19(1):1074. doi: 10.1186/s12885-019-6205-0.
引用本文的文献
1
Immunotherapy in Esophagogastric Cancer: Treatment Landscape, Challenges, and New Directions.免疫疗法在胃食管交界处癌中的应用：治疗现状、挑战与新方向。
J Gastrointest Cancer. 2024 Mar;55(1):153-167. doi: 10.1007/s12029-023-01000-8. Epub 2023 Dec 21.
本文引用的文献
1
Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3).纳武利尤单抗治疗既往治疗的晚期食管鳞癌患者的 3 年随访和应答生存关系（ATTRACTION-3）。
Clin Cancer Res. 2022 Aug 2;28(15):3277-3286. doi: 10.1158/1078-0432.CCR-21-0985.
2
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.纳武利尤单抗联合治疗晚期食管鳞癌。
N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380.
3
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.效应 T 细胞和调节性 T 细胞之间的 PD-1 表达平衡可预测 PD-1 阻断疗法的临床疗效。
Nat Immunol. 2020 Nov;21(11):1346-1358. doi: 10.1038/s41590-020-0769-3. Epub 2020 Aug 31.
4
CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.CX3CR1 鉴定了在癌症化疗免疫治疗期间能够耐受化疗的 PD-1 治疗反应性 CD8+ T 细胞。
JCI Insight. 2018 Apr 19;3(8). doi: 10.1172/jci.insight.97828.
5
PD-1 blockade induces responses by inhibiting adaptive immune resistance.程序性死亡受体1（PD-1）阻断通过抑制适应性免疫抵抗来诱导反应。
Nature. 2014 Nov 27;515(7528):568-71. doi: 10.1038/nature13954.
Zotero 插件